Digoxin Medulloblastoma Study

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Study ID
NCT06701812
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Months - 30 Years
Healthy Volunteers
Not accepted

Interventions

  • Digoxin — DRUG
    2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.

Study Details

The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

Key Dates

First listed
Nov 22, 2024
Start date
Jan 15, 2026
Status verified
Aug 2026
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
23 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Digoxin Treatment
    Digoxin will be administered orally at a standard maintenance dosing. Each cycle will be 28 days.

Primary Outcome Measure

Progression Free Survival at 4 months (PFS4) [ Time Frame: 4 months ]

Central Contacts

Locations (17)

FacilityCityStateZIPSite coordinators
University of Alabama at Birmingham Children's of AlabamaBirminghamAlabama35233
Laura Metrock, MD (PRINCIPAL_INVESTIGATOR)
Phoenix Childrens HospitalPhoenixArizona85016
Ross Mangum, MD (PRINCIPAL_INVESTIGATOR)
Arkansas Childrens HospitalLittle RockArkansas72202
David Douglass, MD (PRINCIPAL_INVESTIGATOR)
Connecticut Children's Medical CenterHartfordConnecticut06106
Michael Isakoff, MD (PRINCIPAL_INVESTIGATOR)
Children's National Medical CenterWashington D.C.District of Columbia20010
Eugene Hwang, MD (PRINCIPAL_INVESTIGATOR)
Nemours JacksonvilleJacksonvilleFlorida32207
Darren Klawinski, MD (PRINCIPAL_INVESTIGATOR)
University of MiamiMiamiFlorida33136
Bradley Gampel, MD (PRINCIPAL_INVESTIGATOR)
Johns Hopkins All Children'sSt. PetersburgFlorida33701
Stacie Stapleton, MD (PRINCIPAL_INVESTIGATOR)
St. Joseph's Children's HospitalTampaFlorida33607
Trisha Larkin, MD (PRINCIPAL_INVESTIGATOR)
University of KentuckyLexingtonKentucky40536
Tom Badgett, MD, PhD (PRINCIPAL_INVESTIGATOR)
Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterBaltimoreMaryland21218
Kenneth Cohen, MD (PRINCIPAL_INVESTIGATOR)
Washington University St. LouisSt LouisMissouri63130
Mohamed Abdelbaki, MD (PRINCIPAL_INVESTIGATOR)
Montefiore Medical CenterThe BronxNew York10467
Alice Lee, MD (PRINCIPAL_INVESTIGATOR)
UNC Lineberger Comprehensive Cancer CenterChapel HillNorth Carolina27514
David Kram, MD (PRINCIPAL_INVESTIGATOR)
Levine Cancer InstituteCharlotteNorth Carolina28204
Erin Trovillion, MD (PRINCIPAL_INVESTIGATOR)
Vanderbilt University Medical CenterNashvilleTennessee37232
Scott Borinstein, MD (PRINCIPAL_INVESTIGATOR)
UT SouthwesternDallasTexas75390
Matthew Campbell, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

Nationwide
Brain cancer trialsOncology trialsNeuro-oncology trials
By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University of Alabama at Birmingham Children's of Alabama· Birmingham, ALPhoenix Childrens Hospital· Phoenix, AZArkansas Childrens Hospital· Little Rock, ARConnecticut Children's Medical Center· Hartford, CTChildren's National Medical Center· Washington D.C., DCNemours Jacksonville· Jacksonville, FL

Related Studies